STAT+: Pharmalittle: FDA rejects Lilly drug studied only in China; AstraZeneca suffers a setback with a key cancer drug
The Food and Drug Administration declined to approve an Eli Lilly (LLY) lung cancer drug that had been studied only in China.
Good morning, everyone, and how are you today? We are doing just fine, thank you, despite the cloudy skies looming over the Pharmalot campus.
